Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Tokyo - Delayed Quote JPY

ReproCELL Incorporated (4978.T)

Compare
132.00
-7.00
(-5.04%)
At close: April 4 at 3:30:00 PM GMT+9
Loading Chart for 4978.T
  • Previous Close 139.00
  • Open 136.00
  • Bid 132.00 x --
  • Ask 133.00 x --
  • Day's Range 127.00 - 139.00
  • 52 Week Range 97.00 - 277.00
  • Volume 2,041,000
  • Avg. Volume 4,064,520
  • Market Cap (intraday) 12.438B
  • Beta (5Y Monthly) 0.79
  • PE Ratio (TTM) --
  • EPS (TTM) -1.28
  • Earnings Date May 12, 2025 - May 16, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, pluripotent stem cells, and synfire induced neurons; 3D cell culture; and labware. The company also provides research stem cell, genomics, clinical stem cell research, preclinical and drug discovery CRO, precision medicine, human tissue samples, clinical laboratory, diagnostic, and gene editing services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.

www.reprocell.com

96

Full Time Employees

March 31

Fiscal Year Ends

Recent News: 4978.T

View More

Performance Overview: 4978.T

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

4978.T
26.92%
Nikkei 225 (^N225)
15.33%

1-Year Return

4978.T
13.16%
Nikkei 225 (^N225)
15.07%

3-Year Return

4978.T
41.85%
Nikkei 225 (^N225)
21.79%

5-Year Return

4978.T
57.00%
Nikkei 225 (^N225)
89.56%

Compare To: 4978.T

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4978.T

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    12.44B

  • Enterprise Value

    8.01B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.57

  • Price/Book (mrq)

    1.40

  • Enterprise Value/Revenue

    2.94

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -4.05%

  • Return on Assets (ttm)

    -1.92%

  • Return on Equity (ttm)

    -1.32%

  • Revenue (ttm)

    2.72B

  • Net Income Avi to Common (ttm)

    -110M

  • Diluted EPS (ttm)

    -1.28

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.43B

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 4978.T

View More

Company Insights: 4978.T

Research Reports: 4978.T

View More

People Also Watch